Get notified when NSRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Dilution Per Share to New Investors $2.29 (new) — New investors will experience immediate and substantial dilution of $2.29 per share, representing a significant portion of the $3.65 offering price.
- 2,695,425 Ordinary Shares Issuable Upon the Exercise of Warrants Issued In a Private Placement Offering In February 2026, At an Exercise Price of $6.53 Per Ordinary Share (new) — A large warrant overhang from a recent private placement could lead to further dilution if exercised, though the exercise price is above the current market price.
Nasus Pharma files for up to $8.5M at-the-market offering of Ordinary Shares
Filed September 18, 2026 · ~2 min read
Key Changes
-
high
Nasus Pharma is offering up to $8.5 million of Ordinary Shares in an at-the-market program; actual proceeds are not determinable and no shares may be sold.
The Offering verify on EDGAR → -
high
Net proceeds are earmarked for clinical development of NS002 for anaphylaxis, initiation of other pipeline studies, and working capital.
Use of Proceeds verify on EDGAR → -
high
New investors face dilution of $2.29 per share, with additional dilution from outstanding options and warrants.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (LAC 10-Q) is open in full — no account needed.
Partner
Trade NSRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 21, 2026 · How we verify